Prices are updated after-hours
Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Vaccine    save search
Vaccine research market size to grow at a CAGR of 9.88% from 2022 to 2027, Abbott Laboratories, Astellas Pharma Inc., AstraZeneca Plc, more to emerge as key players, Technavio
Published: 2024-03-11 (Crawled : 14:30) - prnewswire.com
CMXHF | $172.54 -19.21% 50 twitter stocktwits trandingview |
n/a
 | | O: 0.41% H: 0.0% C: 0.0%
CSLLY | $86.918 3.3% 60K twitter stocktwits trandingview |
n/a
 | | O: -4.92% H: 3.76% C: 3.44%
GLAXF | News | $20.2 -14.18% 510 twitter stocktwits trandingview |
Health Technology
 | | O: -3.4% H: 1.49% C: 1.49%
AZNCF | News | $138.24 -4.19% 800 twitter stocktwits trandingview |
Health Technology
 | | O: 1.55% H: 0.82% C: 0.16%
ALPMY | $9.47 -1.11% 520K twitter stocktwits trandingview |
Manufacturing
 | | O: -1.41% H: 5.06% C: 4.01%
GSK | News | $39.75 1.22% 0.0% 1.6M twitter stocktwits trandingview |
Health Technology
 | | O: -0.6% H: 0.19% C: 0.09%
ABT | News | $107.28 1.91% 0.18% 10M twitter stocktwits trandingview |
Health Technology
 | | O: 0.26% H: 0.0% C: 0.0%
SNY | News | $46.32 2.05% 2.01% 3.3M twitter stocktwits trandingview |
Health Technology
 | | O: 0.57% H: 0.0% C: 0.0%
AZN | News | $68.56 0.29% 0.29% 4.7M twitter stocktwits trandingview |
Health Technology
 | | O: 1.08% H: 0.82% C: 0.67%
pharma vaccine astrazeneca research key market
Transgene, NEC, and BostonGene Expand Collaboration for Phase I/II Clinical Trial of Neoantigen Cancer Vaccine TG4050
Published: 2024-03-05 (Crawled : 07:00) - globenewswire.com
NIPNF | $68.91 -52.94% 120 twitter stocktwits trandingview |
Technology Services
 | Email alert Add to watchlist
tg4050 vaccine cancer collaboration trial
Takeda and Biological E. Limited Collaborate to Accelerate Access to Dengue Vaccine in Endemic Areas
Published: 2024-02-27 (Crawled : 09:00) - biospace.com/
TAK | News | $13.24 0.61% 0.0% 1.3M twitter stocktwits trandingview |
Health Technology
 | | O: 0.0% H: 0.47% C: 0.2%
vaccine dengue tak-003 qdenga
IMNN-101 Preclinical Data in SARS CoV-2 Published in Peer-Reviewed Journal Vaccine
Published: 2024-02-22 (Crawled : 13:00) - globenewswire.com
IMNN | $1.16 3.11% 3.02% 95K twitter stocktwits trandingview |
Manufacturing
 | | O: 1.73% H: 5.49% C: 3.44%
imnn-101 vaccine preclinical
Novavax and Gavi Reach Settlement on 2021 COVID-19 Vaccine Advance Purchase Agreement
Published: 2024-02-22 (Crawled : 11:00) - prnewswire.com
NVAX | $3.99 2.57% 2.51% 2.9M twitter stocktwits trandingview |
Health Technology
 | | O: 12.06% H: 22.42% C: 9.42%
covid-19 vaccine reach agreement
ImmunityBio Announces Full Accrual of First Two Phases of Cancer Vaccine Trial in Participants with Lynch Syndrome and Initiation of Randomized Controlled Phase of the Trial
Published: 2024-02-21 (Crawled : 15:00) - biospace.com/
IBRX | $5.265 7.23% 6.74% 4.6M twitter stocktwits trandingview |
Manufacturing
 | | O: 1.27% H: 0.31% C: -2.3%
first vaccine cancer trial
Evaxion Announces Successful Completion of the Initial Phases of Ongoing Vaccine Collaboration with MSD
Published: 2024-02-20 (Crawled : 12:30) - globenewswire.com
EVAX | $4.2 -0.47% -0.48% 31K twitter stocktwits trandingview |
Manufacturing
 | | O: 9.14% H: 1.81% C: -9.73%
vaccine ongoing collaboration
Vaxxinity’s Cholesterol Vaccine Candidate Successfully Lowers LDL-C: Preclinical Data Published
Published: 2024-02-15 (Crawled : 13:00) - globenewswire.com
VAXX | News | $0.4761 2.43% 2.37% 290K twitter stocktwits trandingview |
| | O: -1.25% H: 0.0% C: -9.96%
candidate vaccine cholesterol preclinical
Ginkgo Bioworks and SaponiQx Awarded MCDC Contract to Discover and Manufacture Next-Generation Vaccine Adjuvants Using Generative Molecular Design
Published: 2024-02-15 (Crawled : 12:00) - prnewswire.com
AGEN | $5.3 6.64% 6.23% 1.5M twitter stocktwits trandingview |
Health Technology
 | | O: -7.32% H: 0.0% C: -23.98%
vaccine contract molecular
GeoVax Reports Positive Interim Data From Phase 2 Clinical Trial of GEO-CM04S1 as a Universal Covid-19 Vaccine Booster
Published: 2024-02-06 (Crawled : 14:00) - globenewswire.com
GOVX | $1.59 4.61% 4.4% 19K twitter stocktwits trandingview |
Health Technology
 | | O: 2.77% H: 2.69% C: 1.92%
cm04 covid-19 vaccine universal geo-cm04s1 positive trial
New COVID-19 sa-mRNA Results from CSL and Arcturus Therapeutics Demonstrate Longer Duration of Immunity Compared to Conventional COVID-19 mRNA Vaccine Booster - February 5, 2024
Published: 2024-02-05 (Crawled : 14:30) - biospace.com/
ARCT 4 | $25.995 -1.23% -1.25% 630K twitter stocktwits trandingview |
Health Technology
 | | O: -0.29% H: 2.11% C: 1.3%
covid-19 vaccine mrna therapeutics results
New COVID-19 sa-mRNA Results from CSL and Arcturus Therapeutics Demonstrate Longer Duration of Immunity Compared to Conventional COVID-19 mRNA Vaccine Booster
Published: 2024-02-05 (Crawled : 13:30) - prnewswire.com
ARCT 4 | $25.995 -1.23% -1.25% 630K twitter stocktwits trandingview |
Health Technology
 | | O: -0.29% H: 2.11% C: 1.3%
covid-19 vaccine mrna therapeutics results
Vaxart Announces Publication in Vaccines of Non-Human Primate Preclinical Data Demonstrating Its Next-Generation Vaccine Candidates Elicit Mucosal and Systemic Immunogenicity and Reduce Viral Shedding after SARS-CoV-2 Challenge
Published: 2024-02-05 (Crawled : 13:00) - globenewswire.com
VXRT | News | $0.7652 -9.15% -10.08% 1.9M twitter stocktwits trandingview |
Health Technology
 | | O: 0.83% H: 4.13% C: -3.72%
primate vaccine sars-cov-2 publication preclinical
Capricor Therapeutics Announces Collaboration with the National Institutes of Health for Clinical Trial of Novel Exosome-Based Multivalent Vaccine for SARS-CoV-2
Published: 2024-01-24 (Crawled : 14:30) - globenewswire.com
CAPR | $5.01 -0.79% -0.8% 350K twitter stocktwits trandingview |
Health Technology
 | | O: 2.18% H: 6.4% C: -3.32%
vaccine sars-cov-2 collaboration trial therapeutics
Anixa Biosciences Announces Japanese Patent on Ovarian Cancer Vaccine Technology
Published: 2024-01-23 (Crawled : 13:30) - biospace.com/
ANIX | $3.12 0.65% 0.64% 33K twitter stocktwits trandingview |
Health Technology
 | | O: 0.0% H: 3.09% C: 1.03%
patent vaccine cancer technology
CORBEVAX®, A COVID19 VACCINE DEVELOPED BY BIO E-INDIA BASED ON THE RBD PROTEIN ANTIGEN TECHNOLOGY FROM TEXAS CHILDREN'S HOSPITAL CENTER FOR VACCINE DEVELOPMENT, RECEIVES WORLD HEALTH ORGANIZATION EMERGENCY USE LISTING APPROVAL
Published: 2024-01-22 (Crawled : 18:00) - prnewswire.com
OVV | $51.98 0.87% 0.0% 1.8M twitter stocktwits trandingview |
Energy Minerals
 | | O: -0.49% H: 1.94% C: 1.42%
covid19 corbevax vaccine health world approval hospital protein technology
Global Respiratory Disease Vaccine Market Set for Growth, Fueled by Aging Populations and Vaccine Mandates - Trends, Opportunities, and Forecasts, 2018-2028F
Published: 2024-01-22 (Crawled : 17:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 600K twitter stocktwits trandingview |
Health Technology
 | | O: 1.71% H: 0.0% C: -0.15%
AZNCF | News | $138.24 -4.19% 800 twitter stocktwits trandingview |
Health Technology
 | | O: 2.63% H: 0.8% C: 0.75%
JNJ | News | $147.91 1.49% -0.03% 9.6M twitter stocktwits trandingview |
Health Technology
 | | O: 0.6% H: 0.0% C: 0.0%
SNY | News | $46.32 2.05% 2.01% 3.3M twitter stocktwits trandingview |
Health Technology
 | | O: -0.21% H: 0.0% C: 0.0%
AZN | News | $68.56 0.29% 0.29% 4.7M twitter stocktwits trandingview |
Health Technology
 | | O: 1.8% H: 0.14% C: -0.89%
disease vaccine respiratory global set market
Vaxart Receives $9.27 Million BARDA Project NextGen Award to Prepare for Phase 2b Clinical Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate
Published: 2024-01-19 (Crawled : 13:30) - globenewswire.com
VXRT | News | $0.7652 -9.15% -10.08% 1.9M twitter stocktwits trandingview |
Health Technology
 | | O: 2.1% H: 1.04% C: -8.52%
covid-19 award candidate vaccine million nextgen study
Elicio Therapeutics to Present ELI-002 7P (AMPLIFY-7P) Trial in Progress Poster on Phase 1/2 Study of Lymph Node-Targeted Vaccine at ASCO GI Symposium
Published: 2024-01-17 (Crawled : 13:30) - globenewswire.com
ELTX | $8.465 2.86% 2.78% 28K twitter stocktwits trandingview |
| | O: 1.89% H: 0.0% C: -5.58%
eli-002 vaccine symposium asco trial therapeutics study
Emergent BioSolutions Awarded Procurement Contract Valued up to $235.8 Million to Supply BioThrax® (Anthrax Vaccine Adsorbed) to the U.S. Department of Defense
Published: 2024-01-11 (Crawled : 13:00) - globenewswire.com
EBS | $2.04 9.68% 0.49% 930K twitter stocktwits trandingview |
Health Technology
 | | O: 3.69% H: 0.0% C: -6.67%
biothrax defense vaccine contract million
Gainers vs Losers
67% 33%

Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M twitter stocktwits trandingview |
Finance
EGOX | $0.0515 43.06% 30.1% 330M twitter stocktwits trandingview |

OLB 4 | $0.33 -14.95% 25.53% 840K twitter stocktwits trandingview |
Technology Services
NVFY | $2.77 31.28% 23.83% 33M twitter stocktwits trandingview |
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M twitter stocktwits trandingview |
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M twitter stocktwits trandingview |
Distribution Services
INSG | $3.03 25.21% 20.13% 330K twitter stocktwits trandingview |
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K twitter stocktwits trandingview |
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M twitter stocktwits trandingview |

ASNS | $0.828 21.75% 17.86% 18K twitter stocktwits trandingview |

Your saved searches
Save your searches and get alerts when important news are released.